D.A. Davidson & CO. Has $2.05 Million Stock Position in Guardant Health, Inc. $GH

D.A. Davidson & CO. grew its holdings in shares of Guardant Health, Inc. (NASDAQ:GH) by 66.1% in the second quarter, Holdings Channel reports. The institutional investor owned 39,313 shares of the company’s stock after acquiring an additional 15,644 shares during the period. D.A. Davidson & CO.’s holdings in Guardant Health were worth $2,046,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the business. Values First Advisors Inc. grew its holdings in shares of Guardant Health by 9.9% during the second quarter. Values First Advisors Inc. now owns 32,539 shares of the company’s stock valued at $1,693,000 after buying an additional 2,942 shares during the last quarter. Praxis Investment Management Inc. acquired a new position in shares of Guardant Health during the second quarter valued at about $212,000. Allianz Asset Management GmbH lifted its position in shares of Guardant Health by 10.1% during the second quarter. Allianz Asset Management GmbH now owns 159,348 shares of the company’s stock valued at $8,292,000 after purchasing an additional 14,672 shares in the last quarter. TD Asset Management Inc lifted its position in shares of Guardant Health by 272.0% during the second quarter. TD Asset Management Inc now owns 162,600 shares of the company’s stock valued at $8,462,000 after purchasing an additional 118,886 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC lifted its position in shares of Guardant Health by 18.3% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 8,262 shares of the company’s stock valued at $430,000 after purchasing an additional 1,280 shares in the last quarter. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other Guardant Health news, CEO Helmy Eltoukhy sold 300,000 shares of Guardant Health stock in a transaction dated Tuesday, September 9th. The shares were sold at an average price of $59.45, for a total value of $17,835,000.00. Following the sale, the chief executive officer owned 2,123,499 shares of the company’s stock, valued at approximately $126,242,015.55. The trade was a 12.38% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Medina Manuel Hidalgo sold 2,165 shares of Guardant Health stock in a transaction dated Friday, September 12th. The stock was sold at an average price of $54.16, for a total transaction of $117,256.40. Following the completion of the sale, the director directly owned 851 shares in the company, valued at approximately $46,090.16. This represents a 71.78% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 302,691 shares of company stock worth $17,984,628. Insiders own 6.10% of the company’s stock.

Guardant Health Stock Performance

Shares of GH stock opened at $72.15 on Monday. The firm has a market cap of $9.00 billion, a price-to-earnings ratio of -21.54 and a beta of 1.53. Guardant Health, Inc. has a 52 week low of $20.14 and a 52 week high of $72.70. The firm’s 50-day simple moving average is $62.25 and its two-hundred day simple moving average is $51.95.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings data on Wednesday, July 30th. The company reported ($0.44) EPS for the quarter, topping the consensus estimate of ($0.52) by $0.08. The company had revenue of $232.09 million during the quarter, compared to the consensus estimate of $211.19 million. The business’s revenue was up 31.0% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.84) EPS. Guardant Health has set its FY 2025 guidance at EPS. Analysts forecast that Guardant Health, Inc. will post -2.9 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. UBS Group raised their price target on shares of Guardant Health from $70.00 to $80.00 and gave the company a “buy” rating in a research report on Thursday, September 25th. Canaccord Genuity Group raised their price target on shares of Guardant Health from $65.00 to $75.00 and gave the company a “buy” rating in a research report on Friday, September 26th. Mizuho raised their price target on shares of Guardant Health from $65.00 to $70.00 and gave the company an “outperform” rating in a research report on Thursday, September 25th. Raymond James Financial raised their price target on shares of Guardant Health from $59.00 to $61.00 and gave the company an “outperform” rating in a research report on Thursday, July 31st. Finally, Cowen reissued a “buy” rating on shares of Guardant Health in a research report on Thursday, September 25th. Twenty-three investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $67.29.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.